Tech Company Financing Transactions
Rakuten Aspyrian Funding Round
Rakuten Aspyrian closed a $150 million Series C financing round on 8/24/2018. Backers included private investors.
Transaction Overview
Company Name
Announced On
8/24/2018
Transaction Type
Venture Equity
Amount
$150,000,000
Round
Series C
Investors
private investors (Lead Investor) (Hiroshi Mikitani)
Proceeds Purpose
The financing will also support manufacturing scale-up for the commercialization of ASP-1929 and corporate growth including the initial buildup of commercial operations to support the launch of ASP-1929 in the United States, Japan and Europe.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11080 Roselle St.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Rakuten Aspyrian, Inc., is a privately funded clinical stage biotechnology company with offices in the USA, Japan and Germany. Rakuten Aspyrian has been developing new anticancer therapies based on the Photoimmunotherapy platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Hiroshi Mikitani
Chief Executive Officer
Miguel Garcia-Guzman
Chief Medical Officer
Merrill Biel
Chief Technical Officer
Carlos Garcia
VP - Bus. Development
Abhijit Bhatia
VP - Finance
Agatha Martindale
VP - General Counsel
Isaac Dye
VP - Human Resources
Suzane San
VP - Operations
Lola Fong
VP - Operations
Minami Maeda
Browse more venture capital transactions:
Prev: 8/24/2018: Bungalow venture capital transaction
Next: 8/24/2018: Sitetracker venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs